Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)

Barrett‐Connor, Elizabeth; Weiß, Thomas; McHorney, Colleen A.; Miller, P. D.; Siris, Ethel S.

doi:10.1007/s00198-008-0748-2

Cited by 107 publications

(83 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If TSH !0.20 mU/l, free thyroxine (FT 4 ) and total triiodothyronine (T 3 ) were measured, and if TSH O4.0 mU/l, FT 4 and thyroid peroxidase antibodies (TPOAb) were measured. FT 4 was measured by DELFIA FT 4 (total analytical variation !7%, reference range 8-20 pmol/l), T 3 by AutoDELFIA T 3 (total analytical variation !7%, reference range 1.2-2.7 nmol/l) and TPOAb by luminoimmunoassay from B.R.A.H.M.S.…”

Section: Thyroid Function Testsmentioning

confidence: 99%

See 1 more Smart Citation

Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway

Svare

Nilsen

Åsvold

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To prospectively study the relation between TSH and risk of hip and forearm fractures. Design: A population-based cohort study. Methods: In a substudy of the second survey of the Nord Trøndelag Health Study, Norway (HUNT2, 1995-97), linked with a hospital-based fracture registry, we investigated the relation between baseline TSH and risk of hip and/or forearm fractures. Population: A total of 16 610 women and 8595 men aged 40 years or more, without previous self-reported thyroid disease and hip or forearm fractures. Results: During 12.5 years follow-up, a total of 1870 women and 342 men experienced hip or forearm fractures. Overall, there was no relation between baseline TSH and fracture risk. However, there was weak evidence that women with TSH !0.5 and O3.5 mU/l had a slightly increased risk of hip fractures (hazard ratio (HR) 1.30, 95% CI 0.97-1.94 and HR 1.19, 95% CI 0.93-1.52) compared with the reference group with TSH of 1.5-2.4 mU/l. Supplementary analyses showed higher hip fracture risk in women with TSH O4.0 mU/l and negative thyroid peroxidase antibodies (TPOAb) compared with the reference group (HR 1.75, 95% CI 1.24-2.46). Conclusion: We found no statistically significant relation between baseline TSH and subsequent fracture risk, but the data suggest a weak positive association with hip fracture risk among women with both low and high TSH. The latter association was confined to women with negative TPOAb status.

show abstract

Section: Thyroid Function Testsmentioning

confidence: 99%

“…Hypothyroidism is a risk factor for falls in elderly individuals (4), and hyperthyroidism has for more than a century been known as a risk factor for osteoporosis (5). Both overt hypothyroidism and hyperthyroidism have been associated with increased risk of fractures in previous studies (6,7,8,9,10,11,12,13,14).…”

Section: Introductionmentioning

confidence: 99%

Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway

Svare

Nilsen

Åsvold

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…While it is an established risk factor for osteoporosis and would generally trigger screening, 9 this study showed advancing age to be associated with a decreased likelihood of completing the screening test; women aged 80 years or older are less likely to be screened. Indeed, increasing age by itself has been identified as a barrier to effective osteoporosis care, along with the presence of dementia, lack of treatment adherence, and inadequate social support among vulnerable elderly patients.…”

Section: Discussionmentioning

confidence: 96%

Predictors of Osteoporosis Screening Completion Rates in a Primary Care Practice

DeJesus

Chaudhry²,

Angstman

et al. 2011

Population Health Management

View full text Add to dashboard Cite

The United States Preventive Services Task Force and the National Osteoporosis Foundation recommend routine osteoporosis screening for women aged 65 years or older. Previous studies have shown that the use of a clinical decision-support tool significantly improves screening rates. In a recently published study, a statistically significant improvement was found in the screening rates for eligible women with use of the tool. To evaluate whether a clinical decision-support tool independently predicts completion of osteoporosis screening tests and to identify predictors of screening completion, we examined the records of 2462 female patients who were eligible for osteoporosis screening but had no prior baseline screening and who were seen in our primary care practices in 2007 and 2008. Patient and provider characteristics and clinic visit type were identified, and their association with screening test completion was statistically analyzed using both univariate and multivariate models. Screening completion rates increased significantly from 2007 to 2008. Factors associated with increased likelihood of screening completion included race, marital status, residence, presence of comorbidity (cancer, rheumatologic disease), and the year and type of visit. Screening was less likely for women aged 80 years or older. The use of a point-of-care decision-support tool not only improved osteoporosis screening rates significantly but appeared to be an independent predictor of screening completion. It potentially can facilitate the systematic and effective delivery of preventive health services to patients in the primary care setting. (Population Health Management 2011;14:243-247)

show abstract

“…As mentioned above, ZOL increases BMD, and thus it could reduce the risk of falls to a certain extent. On the other hand, it is known that osteoporosis can lead to spinal deformities such as thoracic kyphosis due to vertebral compression that alters the structure of the spine, causing weakness of the extensor muscles of the trunk and leading to reduced physical mobility and flexibility [33]. When ZOL increases BMD and improves the bone status, the extensor muscles of the trunk are also improved.…”

Section: Rycina 2 śRednie Liczby Punktów W Poszczególnych Domenach Kmentioning

confidence: 95%

Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Huang¹,

Lin²,

Zhu³

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

 Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosisKwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia AbstractIntroduction: Osteoporosis is characterised by decreased bone mass and weakened bones, with an increased risk of fractures. Osteoporotic fracture, the most serious complication of osteoporosis, is related not only to lower bone mineral density (BMD), but also falls. Osteoporosis and fractures are associated with a decreased health-related quality of life (HRQL). Zoledronic acid (ZOL) is an intravenous once-yearly bisphosphonate that has been shown to be effective and safe in improving BMD and reducing fracture risk in controlled clinical trials. Material and methods:In this self-controlled, prospective trial, 220 postmenopausal women with osteoporosis (mean age 67 years) received a single infusion of ZOL 5 mg at baseline and month 12. BMD, HRQL and Fall Index (FI) were measured at baseline, and months 12 and 24 (before each use of ZOL). The main outcome measures were the changes in lumbar spine and hip BMD and the changes in HRQL, the Short Form-36 questionnaire (SF-36). Additional comparisons were based on the FI. LSD multiple comparisons were used in the comparisons of BMD, SF-36 domain scores and FI. Results: The patients had significantly higher L1-4, total hip, femoral neck and trochanter BMD (P < 0.05) with improved HRQL (P < 0.05) over two years of treatment of once-yearly ZOL 5mg. FI was reduced (P < 0.05) with oral daily elemental calcium and vitamin D in the treatment course. Conclusions: ZOL improves BMD and HRQL, especially in the physical aspects, over two years of treatment in women with postmenopausal osteoporosis, and can help improve balance ability. (Endokrynol Pol 2014; 65 (2): 96-104)

show abstract

Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)

Abstract: This large cohort had sufficient power to identify 18 risk factors that independently predicted a significantly increased risk of falling with a graded increase in risk with increasing number of risk factors.

Cited by 107 publications

References 47 publications

Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway

Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway

Predictors of Osteoporosis Screening Completion Rates in a Primary Care Practice

Kwas zoledronowy stosowany przez dwa lata u Chinek z osteoporozą pomenopauzalną zwiększa gęstość mineralną tkanki kostnej i poprawia jakość życia związaną ze stanem zdrowia

Contact Info

Product

Resources

About